Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Cardiol Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
CRDL
New York
8731
https://www.cardiolrx.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Cardiol Therapeutics Inc
Cardiol Therapeutics Completes Patient Enrollment in its Phase II MAvERIC-Pilot Study Investigating CardiolRx(TM) for Recurrent Pericarditis
- Feb 21st, 2024 12:27 pm
Cardiol Therapeutics Granted Orphan Drug Designation for its Lead Drug Candidate for the Treatment of Pericarditis
- Feb 15th, 2024 12:27 pm
Cardiol Therapeutics Regains Compliance with all Applicable Listing Standards of The Nasdaq Capital Market
- Jan 24th, 2024 12:27 pm
Cardiol Therapeutics Announces it has Exceeded 50% Enrollment in its Phase II ARCHER Trial in Acute Myocarditis
- Jan 9th, 2024 12:27 pm
Cardiol Therapeutics Announces Massachusetts General Hospital, Largest Teaching Hospital of Harvard Medical School, as the 8th Major Medical Centre Participating in MAvERIC-Pilot
- Dec 5th, 2023 12:27 pm
Cardiol Therapeutics Announces Study Results Presented at the 2023 Annual Meeting of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases
- Nov 16th, 2023 10:30 am
Cardiol Therapeutics Announces It Has Exceeded 50% Enrollment in Its Phase II MAvERIC-Pilot Study in Recurrent Pericarditis
- Nov 1st, 2023 11:27 am
Cardiol Therapeutics Receives Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
- Oct 20th, 2023 9:00 pm
Cardiol Therapeutics (NASDAQ: CRDL) Advancements in Therapies for Inflammatory Heart Diseases
- Oct 13th, 2023 1:24 pm
Cardiol Therapeutics releases positive study results of subcutaneously administered cannabidiol
- Oct 11th, 2023 5:05 pm
Cardiol Therapeutics Announces Positive Study Results Demonstrating Cardioprotective Effects of Subcutaneously Administered Cannabidiol in a Model of Heart Failure with Preserved Ejection Fraction
- Oct 10th, 2023 10:00 am
Cardiol Therapeutics to Present at Cantor Fitzgerald 2023 Global Healthcare Conference
- Sep 26th, 2023 11:27 am
Cardiol Therapeutics Announces All Collaborating Clinical Research Centers Now Initiated and Eligible to Enroll Patients in ARCHER, a Phase II Trial of CardiolRx(TM) for the Treatment of Acute Myocarditis
- Sep 19th, 2023 11:27 am
Cardiol Therapeutics to Present at Canaccord Genuity 43rd Annual Growth Conference
- Aug 9th, 2023 11:27 am
Cardiol Therapeutics Reports Results of 2023 Annual General Meeting
- Jun 29th, 2023 2:19 pm
Cardiol Therapeutics to Webcast Virtual Annual General Meeting on June 28th at 4:30 p.m. EDT
- Jun 27th, 2023 11:27 am
Sidoti's Micro-Cap Virtual May Conference
- May 9th, 2023 11:15 am
Scroll